Skip directly to content

CURRENT PUBLICATIONS

2017 |2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992

HIV Activist Learning Modules: Engaging our Community in HIV Prevention Policy Advocacy
March 29, 2017 – To support the efforts of prevention advocates across the United States, TAG's HIV Project has developed a series of modules to help support activists’ capacity needs and to develop advocacy action plans. The slides, handouts, and webinars in each of the four modules focus on how to identify and change the governmental, organizational, and institutional policies that create roadblocks to comprehensive HIV prevention in our communities. The materials are useful for personal education or group discussion on HIV prevention and policy advocacy.

An Activist’s Guide to Tuberculosis Diagnostic Tools
February 2017 - Understanding tuberculosis (TB) diagnosis is critical to understanding why the world is currently failing to end TB. Nearly half of people with TB—over 4 million per year—are undiagnosed, leaving them ill and at risk of death and with the potential to transmit disease to others.  Closing this massive gap will require much better use of the current diagnostic methods, as well as research into faster, simpler, more accurate, and less expensive options.

An Activist’s Guide to Tuberculosis Diagnostic Tools provides an overview of the different tests and strategies for detecting TB, including their benefits and limitations. The guide also makes recommendations for how activists and clinicians can contribute to improved TB diagnosis.

New and Updated HCV Treatment Fact Sheets Now Online
February 2017– New fact sheets on Epclusa, HCV Genotypes, and an updated fact sheet on Viekira XR and Technivie are now available.

Community Mobilization: An Assessment of Mechanisms and Barriers at Community-Based and AIDS Service Organizations in Nine U.S. Metropolitan Areas
January 9, 2017 – New Report Shines Spotlight on Need for More Investments in Community Leadership and Mobilization to End HIV as an Epidemic

The Fair Pricing Coalition Releases New Report Urging Modernization of Existing Laws to Rein in Drug Pricing
December 7, 2016 – The Fair Pricing Coalition announces the release of “Tackling Drug Costs: A 100-Day Roadmap,” an analysis of existing federal statutes and regulations that should be strengthened to dramatically lower the prices of drugs and biologics in the U.S. The report, distributed to the President-elect’s transition team and Congressional leaders, provides a roadmap that can be implemented quickly on the heels of growing bipartisan support for feasible measures to control the skyrocketing costs of prescription medications.

Shortage of Injectable Estrogen a Crisis for Transgender Women
Public health experts call on FDA to better manage drug shortage process.

December 5, 2016―Today, The Fenway Institute of Fenway Health, Callen-Lorde Community Health Center, and Treatment Action Group (TAG) released a policy brief documenting the public health emergency created by a shortage of injectable estrogen, and calling on the U.S. Food and Drug Administration (FDA) to be more proactive in resolving the crisis.

2016 TAGUpdate
December 1, 2016

2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time To Lose
OCTOBER 25, 2016 – Tuberculosis (TB) killed 1.8 million people in 2015, making it the most deadly infectious disease worldwide, but funding for research into better TB prevention, diagnosis, and treatment dropped by US$53.4 million, according to Treatment Action Group’s 2016 Report on Tuberculosis Research Funding Trends, 2005–2015: No Time to Lose. In 2015, the world spent US$620.6 million on TB research and development (R&D), the lowest level of funding since 2008. This marks the second straight year that funding for TB R&D has fallen, raising doubts over whether world leaders will fulfill recent promises to combat antimicrobial resistance (AMR) and eliminate TB by 2035.

Breakthrough: Catalyzing R&D to End TB
October 2016 – There is great hope for ending tuberculosis (TB)—the world’s leading infectious disease—thanks to both scientific progress and increased ambition from policymakers. But achieving this goal will require more investments in research and development (R&D). With funding trends distressingly on the decline for TB R&D, political action is critical to bend the curve up toward the development of breakthrough diagnostics, treatments, and vaccines needed to realize the promise of ending TB.

AN ACTIVIST’S GUIDE TO Tuberculosis Drugs 2016 Update
October 2016 – Tuberculosis (TB) has been curable for decades, but a rise in the number of people living with drugresistant TB (DR-TB) and TB/HIV coinfection challenges global targets of zero TB deaths, new infections, suffering, and stigma. Although TB and the people it affects have changed over the years, for the most part the drugs used against it have not. In 2012, bedaquiline, used to treat DR-TB, became the first new TB drug from a new class to be approved by the U.S. Food and Drug Administration (FDA) in over 40 years; its accelerated approval was followed in 2014 by the European Medicines Agency’s (EMA’s) conditional approval of bedaquiline and another new drug, delamanid, for the treatment of some forms of DR-TB.

TAGline Fall 2016
NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

New and Updated HCV Treatment Fact Sheets Now Online
September 20, 2016 – A new fact sheet on Epclusa is now available for download, in English or Spanish.

2016 Pipeline Report
July 15, 2016 – HIV and TB Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development

Breathing Life into Flatlined U.S. Government Funding for Tuberculosis Research: FY 2017–2020 Allocations and Recommendations
June 2016 – This policy brief provides an overview of investments made by the U.S. government and explains how increasing TB R&D funding can catalyze the development of better vaccines, diagnostics, and treatments for TB. It is built upon resource tracking and reporting done by Treatment Action Group (TAG), and it recommends areas in which investments will not only fill research gaps but also provide clarity in the vision proposed by the National Action Plan and prevent the rising threat of multidrug-resistant TB (MDR-TB).

TAGline Spring 2016 
NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS